Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

This Weeks Free Stock Pick Biotech

|Includes: ABT, AGN, AMGN, AZN, Biogen Inc. (BIIB), BMY, GILD, GSK, JNJ, MYL, NVS, PFE, RHHBY, SNY, TEVA

Biogen

This Weeks Free Stock Pick - Investing in Biotech Earnings Growth

The biotechnology sector' s run over the last few years has been nothing short of astounding. The sector has easily beaten broad market indexes and it has been a leader in the health care space as well thanks to a variety of blockbuster drugs, shifting demographics, and a boost to insurance rolls as of late.

The space remains well-positioned for growth and the medical biomed/genome industry is actually currently ranked in the top 20% overall. In fact, we have over 50 companies in the space that have ranks of 'buy' so there are plenty of great companies to choose from in the biotech world.

Today though, let's take a closer look at a company that is pretty much synonymous with the space and could continue to lead the market higher. That stock is of course Biogen (NASDAQ:BIIB) a biotech company which may be the perfect mix between growth and stability for investors seeking a top choice in the ever-popular biotechnology sector.

Biogen in Focus

Biogen is a Massachusetts-based developer of drugs to treat neurological, autoimmune and hematologic disorders. However, the company has several therapies that help people with Multiple Sclerosis while drugs here (including AVONEX, TECFIDERA, and TYSABRI) account for the bulk of BIIB's revenue.

Beyond the company's solid lineup of drugs right now, investors should note that BIIB also has a great drug pipeline as well. This should help Biogen to prosper in the years to come, assuming of course they can gain FDA approval for at least a few of their in-development drugs. This is very well possible though as BIIB currently has about 20 drugs in trial right now, while it has five in the critical phase 3 of the program.

Analyst Opinion

Analysts tracking BIIB stock are also pretty optimistic in general about the company's near term prospects, as evidenced by some recent earnings estimate revisions for the stock. Current quarter EPS estimates have risen by about seven cents in the past three months up to $3.90/share, while we have seen a move from $16.67/share to $16.89/share for the current year time frame over the past 90 days as well.

These revisions help to push BIIB's growth rates up to very strong levels, and especially so for a big cap company. In fact, earnings are expected to grow 59% for this quarter when compared to the year ago time frame, while the current year numbers are expected to grow a robust 22% when compared to the previous year. Not bad at all for a $100 billion market cap company!

But if that wasn't enough for investors, you should also consider how BIIB does in earnings season, especially since a report for the company is coming up very soon. BIIB has actually beaten estimates in three straight quarters, while its four quarter average shows an earnings beat of over 11%.

Stock Chart Biogen

Thanks to these factors, it shouldn't be too surprising to note that we have assigned Biogen a Zacks Rank #1 (Strong Buy) and are looking for the outperformance to continue. We particularly think it makes sense for growth oriented investors as well, since the stock has a 'B' grade for its Growth Style Score too.

Bottom Line

The biotechnology segment remains a very strong segment of the market continuing its run of outperformance. And while there are a ton of great choices in this market, Biogen should stand out for most.

Not only does the company have great growth prospects thanks to a flurry of drugs in its pipeline, but analysts are on board with the company's trajectory as well. Earnings estimates have been rising and with an earnings release coming up pretty soon, now could be the time to get in on this top ranked large cap stock.

Profit Rocket

Invest2Success "Profit Rockets" Stock Picks
Free Trial - Receive daily low-risk high-reward SP500 NYSE Nasdaq buy-long and short-sell stock picks that are experiencing strong increasing and decreasing earnings, that include buy sell entry, stop-loss, take profit area price targets, and trade management information to your email inbox.

Van Tharp Institute
Van Tharp Institute

Van Tharp Institute
Investing Trading Home Study Programs & Live Seminars Workshops

Dedicated to cutting edge, high quality professional educational investing trading programs for traders and investors providing a road map for financial freedom. The finest investing trading education in the financial universe. Dr Van Tharp is one of the orginal Market Wizards, and referred to as the Traders Coach.

Track n Trade Trading Software

Track n Trade CandleStick Auto-Recognition Plug-in
Quickly identify candlestick patterns without thinking. With Track 'n Trade, you have the ability to click, and select your favorite candle patterns, and have Track 'n Trade find, identify, and even auto-trade each signal through our famed Autopilot Trading System.

Candle Charting Intensive Training

Steve Nisons Candlestick Charting Intensive Training and Software
for Profitably Trading Stocks Forex Futures Commodities

Use the CandleScanner trading software to automatically scan for profitable trading setups on any timeframe. Stock forex and futures candlestick trading courses to throughly understand how to profit from candlestick chart patterns. Free newsletter and live trading webinars. Steve Nison is the authority on trading and profiting using candlesticks.

Live Trading Seminars

Stock Option Forex Futures Training Seminars Webinars Workshops
Click Here For The Complete 2015 Schedule

Professional investors traders teaching successful low-risk high-reward
trade strategies. Power profit secrets for stocks, options, forex, futures
investing trading success. Or avail of Home Study Courses and or
Trading Softwares available to improve your investment returns.